This confirmatory double-blind, placebo-controlled phase III trial evaluated the efficacy, safety, tolerability, and immunological effects of short-course pre-seasonal subcutaneous immunotherapy with mannan-conjugated birch pollen allergoid EP-088_T502 (cumulative dose 28,000 mTU over 8 injections across 6 visits) versus placebo in 278 adults and adolescents with birch pollen-induced allergic rhinoconjunctivitis during the 2025 birch pollen season.
EP-088_T502 significantly reduced the combined symptom and medication score (CSMS) during peak pollen season versus placebo (mean absolute difference −0.31, 95% CI −0.56 to −0.05; p = 0.0169; ~18% median reduction); health-related QoL improved by 20% (p < 0.005); Bet v 1-specific IgG4 rose 6.4-fold versus placebo (p < 0.0001); and the IgE/IgG4 ratio fell 73% from baseline and 69% versus placebo (both p < 0.0001).
The standardised effect size (0.31) fell below the proposed minimally clinically important difference threshold of 0.5 in the primary FAS analysis; the adolescent subgroup was very small (n = 13, only 4.7% of participants), limiting any conclusions for that age group; and pollen-count data from several monitoring stations were incomplete, requiring a sensitivity analysis using weather service forecast data.
A short 6-visit pre-seasonal SCIT course with EP-088_T502 at 28,000 mTU meaningfully reduces birch pollen allergy symptoms and medication use with a strong IgG4 immunological response, but clinicians should note that one grade III systemic reaction occurred (in 5.9% of active-treated participants overall), underscoring the need for standard SCIT safety precautions including 30-minute post-injection observation.
Explore related topics